Last reviewed · How we verify
NCT03424200
Coaching for Cognition in Alzheimer's (COCOA)
NA trial testing Routine care in Alzheimer Disease in 54 participants. Completed in 1 January 2022.
1 January 2022
Quick facts
| Lead sponsor | Hoag Memorial Hospital Presbyterian |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 54 |
| Start date | 10 January 2018 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Routine care
- Coaching plus routine care
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Hoag Memorial Hospital Presbyterian
Who can join
50 and older, any sex, with Alzheimer Disease or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
One major study objective is, using 2 study arms (data-driven health coaching plus RC vs. RC only), to evaluate the efficacy of data-driven health coaching. 'RC only' will serve as the control group. Participants will be enrolled in the trial on the basis of an existence of objective cognitive impairment defined by the MCI Screen (MCIS) and being in one of three functional stages as defined by the Functional Assessment Staging Test (FAST). The three FAST stages correspond to cognitive impairment without functional impairment (FAST 2), cognitive impairment with functional impairment without impairment in instrumental activities of daily living (FAST 3, also known as mild cognitive impairment, MCI), or cognitive impairment with impaired instrumental activities of daily living (FAST 4). Study objectives include measuring treatment related changes in cognitive and functional abilities, quality of life, and biological or biochemical measures. A second major study objective is to analyze longitudinal multi-omic data from individuals on a trajectory of early-stage dementia, to discover correlations between measured variables, and identify models of causation that can further advance knowledge and research in brain degeneration and healthy living
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Coaching for Cognition in Alzheimer's (COCOA) trial: Study design.
Roach JC, Hara J, Fridman D, Lovejoy JC, et al · · 2022 · cited 11× · PMID 35910672 · DOI 10.1002/trc2.12318
Verify or expand the search:
- PubMed search for NCT03424200
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Routine care
Trials testing the same drug.
- NCT07356024 — Effect of Acupressure on Blood Glucose And Anxiety in Elderly With Diabetes · NA · not yet recruiting
- NCT05503238 — The Effects of Mother-infant Skin-to-skin Contact on Stress Response of Preterm Infants · NA · withdrawn
- NCT07081750 — Dyadic Tailored Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge · NA · not yet recruiting
- NCT06987227 — Effects of Intelligent Parent-child Bonding Intervention on the Physical, Psychological and Social Health of Parents of · NA · not yet recruiting
- NCT06883877 — The Effect of a Multi-modal Program on Fear of Cancer Recurrence in Breast Cancer Patients · NA · not yet recruiting
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Hoag Memorial Hospital Presbyterian trials
Trials by the same sponsor.
- NCT06736054 — A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer · Phase 1 · recruiting
- NCT05880394 — Study of Dotatate Imaging in Breast Cancer · Phase 2 · unknown
- NCT04814615 — A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma · Phase 2 · unknown
- NCT04700332 — PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT04883814 — 18F-fluoroestradiol (FES) PET/CT for Breast Cancer · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03424200 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoag Memorial Hospital Presbyterian
- Last refreshed: 26 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03424200.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing